About 200 reports

  • WHAT IS A BIOSIMILAR?
  • What Is a Biosimilar?

Biosimilars in Oncology Report Code: GDHCHT## Published: August 2018 Healthcare TABLE OF CONTENTS (##/ ##) ##.

  • Biosimilar
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • 6.8.1 REIMBURSEMENT OF BIOSIMILARS IN UNITED KINGDOM
  • 11.3 BIOSIMILARS MANUFACTURING CHALLENGES

Note: ##.

  • Biosimilar
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

Global Biosimilars Partnering 2010-2018 Executive Summary Chapter ## – Introduction Chapter ## – Trends in Biosimilars dealmaking ##. ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • World
  • Demand

ZYDUS CADILA Chapter ## Appendix: Abbreviations List of Tables Summary Table : Global Market for Biosimilars, by Type, Through 2022 Table ## : List of Biosimilars Produced in E.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Biosimilars in Clinical Development
  • 6. The Biosimilar Pipeline

THESE TABLES ARE SUMMARIZED IN Figure ##: Waves of Biosimilar Opportunity by Patent Expiry of Innovator Biologics.

  • Biosimilar
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • 3.3.2 Major Biosimilars in the Pipeline
  • Biosimilars Vs Generics

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020) November 2016 ##.

  • Biosimilar
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Biosimilars
  • Concerns with biosimilars

Familiarity with biosimilar IFX ##% of physicians reported having prescribed Remsima to at least one IBD patient & ##% of physicians have prescribed Inflectra to one of their IBD patients Physicians were generally more familiar with Remsima & Inflectra

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • United States
  • Remicade group

GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES FORECAST 2018-2028 ##.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Shares
  • Market Size
  • Biosimilars market opportunities
  • Approval process for biosimilars in US

Factors such as the patients and physician’s willingness to switch to biosimilars and the price advantage of biosimilars over biologics, will provide considerable growth opportunities to biosimilars manufactures.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • Market Size
  • BIOGENERICS
  • BIOSIMILARS

TABLE OF CONTENTS (##/ ##) ##.

  • Biosimilar
  • Medical Biotechnology
  • Market Size
  • Supply
  • Remicade group

Global Biosimilars and Follow-On Biologics Market 2017-2027 ##.

  • Biosimilar
  • World
  • Forecast
  • Market Shares
  • Market Size
  • Biosimilars in South Korea
  • Biosimilars in Brazil

UBS; ##-##.

  • Biosimilar
  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Pfizer Inc.

Biosimilars Real World Evidence: Proving the point ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • World

Biosimilars Market Snapshot Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025 Table ## Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025 Table ## Global Oncology Biosimilars Marke

  • Biosimilar
  • Medical Biotechnology
  • APAC
  • World
  • Market Size

##.

  • Biosimilar
  • Medical Biotechnology
  • Monoclonal Antibody
  • World
  • Market Size

Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 ## Preface ## Scope and Methodology ##. ## Objectives of the Study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimation ##. ##. ## Bottom-Up App

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Size

Commercialisaton of Biosimilars: Multifunctional teamwork for success ##.

  • Biosimilar
  • Medical Biotechnology
  • World

Biosimilars: EU Payer Perspectives ##.

  • Biosimilar
  • Medical Biotechnology
  • Europe

Physician reluctance to use biosimilars interchangeably with the original product may prove to be an issue, albeit one that can be overcome with education efforts.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • United States
  • Forecast

APAC Biosimilar Market, Forecast 2025 ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • Market Size

Global Biosimilar Market Outlook 2022 ##.

  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Size

You can request one free hour of our analyst’s time when you purchase this market report.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • World
  • Market Size

PHARMA LEADER SERIES: ## TOP BIOSIMILAR DRUG MANUFACTURERS 2017-2027 ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • China
  • Company

The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events ##.

  • Biosimilar
  • Medical Biotechnology
  • United States
  • Forecast
  • Market Size

Biosimilars Market Access in the EU EXECUTIVE SUMMARY A regulatory pathway governing biosimilars in Europe has existed for over a decade Biosimilar developers need to overcome a plethora of IP and legal obstacles Biosimilar naming and labeling in the EU is uniform

  • Biosimilar
  • Europe
  • European Union
  • Italy
  • United Kingdom

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 ##.

  • Biosimilar
  • Insulin
  • Medical Biotechnology
  • World
  • Market Size

Biosimilars: US Payer Perspectives ##.

  • Biopharmaceutical
  • Biosimilar
  • Medical Biotechnology
  • United States

Biosimilar Insulin Market Access EXECUTIVE SUMMARY US Insights and strategic recommendations US payers are adopting a wait-and-see approach for biosimilar Basaglar Bibliography FIVE MAJOR EU MARKETS Insights and strategic recommendations Uptake of biosimilar insulin varies

  • Biosimilar
  • Insulin
  • Medical Biotechnology
  • European Union
  • Market Description

Biosimilars Market, Europe, Forecast to 2025 ##.

  • Biosimilar
  • Medical Biotechnology
  • Europe
  • Forecast